Subventions et des contributions :

Titre :
StressMarq biosciences - alpha synuclein oligomer antibody validation
Numéro de l’entente :
EGP
Valeur d'entente :
25 000,00 $
Date d'entente :
14 juin 2017 -
Organisation :
Conseil de recherches en sciences naturelles et en génie du Canada
Location :
Colombie-Britannique, Autre, CA
Numéro de référence :
GC-2017-Q1-00510
Type d'entente :
subvention
Type de rapport :
Subventions et des contributions
Renseignements supplémentaires :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019)

Nom légal du bénéficiaire :
Christie, Brian (University of Victoria)
Programme :
Subventions d'engagement partenarial pour les universités
But du programme :

This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'sx000D
laboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasx000D
prion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromx000D
endogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of Lewyx000D
Body dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'sx000D
patients have this pathology). The project will involve "mapping" the expression of the pathology and activityx000D
of the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingx000D
controlled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workx000D
with cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesex000D
cells, and if successful, the same could be carried out in rats.